Walvax Biotechnology: The freeze-dried herpes zoster virus mRNA vaccine has officially launched Phase I clinical trials.

Walvax Biotechnology announced that the lyophilized herpes zoster mRNA vaccine, jointly developed by its subsidiary together with Fudan University and Blue Magpie Biotechnology, has completed preparations for a Phase I clinical trial; the company held a Phase I clinical trial kick-off meeting today, officially launching the Phase I clinical trial.